Research graph
References from Nanoparticle-based therapeutics for chronic kidney disease: Emerging advances and AI-driven innovations. Local targets link to admitted publications; unresolved targets remain external evidence.
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
2024 · External reference
Chronic kidney disease
10.1016/s0140-6736(21)00519-5 · 2021 · External reference
Chronic kidney disease
2025 · External reference
Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects
10.1007/s00441-011-1275-6 · 2012 · External reference
Where are they now: spatial and molecular diversity of tissue-resident macrophages in the kidney
10.1016/j.semnephrol.2022.10.002 · 2022 · External reference
National trends and projection of chronic kidney disease incidence according to etiology from 1990 to 2030 in Iran: a Bayesian age-period-cohort modeling study
10.4178/epih.e2023027 · 2023 · External reference
Chronic kidney disease and the global public health agenda: an international consensus
10.1038/s41581-024-00820-6 · 2024 · External reference
Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?
10.2215/cjn.03740907 · 2008 · External reference
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule
10.1016/j.kint.2020.07.019 · 2020 · External reference
TGF-β1 signaling: immune dynamics of chronic kidney diseases
10.3389/fmed.2021.628519 · 2021 · External reference
GFR estimation: from physiology to public health
10.1053/j.ajkd.2013.12.006 · 2014 · External reference
Promoting plant-based therapies for chronic kidney disease
10.1177/2515690x221079688 · 2022 · External reference
Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery
10.1007/s12274-018-2100-2 · 2018 · External reference
Prescription practices in patients with mild to moderate CKD in India
10.1016/j.ekir.2021.06.011 · 2021 · External reference
Advances in kidney-targeted drug delivery systems
10.1016/j.ijpharm.2020.119679 · 2020 · External reference
A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease
2020 · External reference
Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions
10.1016/j.jconrel.2021.04.016 · 2021 · External reference
Kidney-targeted redox scavenger therapy prevents cisplatin-induced acute kidney injury
2021 · External reference
Impact of particle elasticity on particle-based drug delivery systems
10.1016/j.addr.2016.01.007 · 2017 · External reference
Effect of the surface modification, size, and shape on cellular uptake of nanoparticles
10.1002/cbin.10459 · 2015 · External reference
Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases
10.1016/j.nano.2015.04.015 · 2015 · External reference
Size and shape effects in the biodistribution of intravascularly injected particles
10.1016/j.jconrel.2009.10.014 · 2010 · External reference
Impact of nanotechnology on drug delivery
10.1021/nn900002m · 2009 · External reference
Application of nanoparticles in the diagnosis and treatment of chronic kidney disease
2023 · External reference
Targeted therapy of kidney disease with nanoparticle drug delivery materials
2024 · External reference
Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery
10.1002/adma.201104763 · 2012 · External reference
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
10.1186/1477-3155-9-55 · 2011 · External reference
Nanotechnology for the environment and medicine
10.2174/1389557515666150709105129 · 2016 · External reference
Image‐guided tumor surgery: the emerging role of nanotechnology
10.1002/wnan.1624 · 2020 · External reference
Strategic use of nanotechnology in drug targeting and its consequences on human health: a focused review
2019 · External reference
The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations—a narrative review
10.1007/s12672-025-02469-4 · 2025 · External reference
From bits to atoms: machine learning and nanotechnology for cancer therapy
10.26502/jnr.2688-85210042 · 2024 · External reference
Artificial intelligence in chronic kidney diseases: methodology and potential applications
10.1007/s11255-024-04165-8 · 2025 · External reference
Artificial intelligence-assisted design of nanomedicines for breast cancer diagnosis and therapy: advances, challenges, and future directions
10.1007/s12668-025-01980-w · 2025 · External reference
Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology
10.3934/bioeng.2024026 · 2024 · External reference
Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review
10.1007/s12672-025-01821-y · 2025 · External reference
Artificial intelligence in revolutionizing kidney care and beyond: Kid-AI revolution
2024 · External reference
Nanomedicines for renal disease: current status and future applications
10.1038/nrneph.2016.156 · 2016 · External reference
Nanomaterials for targeted therapy of kidney diseases: strategies and advances
2025 · External reference
Renal clearance of quantum dots
10.1038/nbt1340 · 2007 · External reference
Mechanism of hard-nanomaterial clearance by the liver
10.1038/nmat4718 · 2016 · External reference
Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles
10.1016/j.biomaterials.2010.03.048 · 2010 · External reference
Influence of surface chemistry and morphology of nanoparticles on protein corona formation
10.1002/wnan.1788 · 2022 · External reference
Recent advances in understanding the protein Corona of nanoparticles and in the formulation of “Stealthy” nanomaterials
10.3389/fbioe.2020.00166 · 2020 · External reference
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface
10.1038/nnano.2012.237 · 2013 · External reference
Quantitative assessment of nanoparticle biodistribution by Fluorescence Imaging, revisited
10.1021/acsnano.8b02881 · 2018 · External reference
Physiological principles underlying the kidney targeting of renal nanomedicines
10.1038/s41581-024-00819-z · 2024 · External reference
RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis
10.1016/j.trsl.2024.03.003 · 2024 · External reference
A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis
10.1073/pnas.2305662120 · 2023 · External reference
High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches
10.1038/s41467-025-56223-z · 2025 · External reference
Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
10.1016/j.toxrep.2020.12.022 · 2021 · External reference
Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
10.1016/j.jconrel.2021.11.042 · 2022 · External reference
Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients
10.1016/j.jconrel.2023.09.003 · 2023 · External reference
Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions
10.1186/s12989-017-0206-4 · 2017 · External reference
Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys
10.2147/ijn.s443168 · 2024 · External reference
Minimum information reporting in bio–nano experimental literature
10.1038/s41565-018-0246-4 · 2018 · External reference
Nephrotoxicity induced by different diameters of sphere gold nanoparticles with special emphasis on the nephroprotective role of quercetin
10.5455/ovj.2023.v13.i6.7 · 2023 · External reference
Effects of cerium oxide nanoparticles on adenine‐induced chronic kidney disease model rats
10.1111/ggi.14739 · 2024 · External reference
Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice
10.1038/s42003-021-02546-8 · 2021 · External reference
KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · 2024 · External reference
Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity
10.1016/j.tox.2010.08.013 · 2010 · External reference
Research and application prospect of nanomedicine in kidney disease: a bibliometric analysis from 2003 to 2024
10.2147/ijn.s510016 · 2025 · External reference
The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis
10.3389/fphar.2023.1335094 · 2024 · External reference
NF-κB in biology and targeted therapy: new insights and translational implications
10.1038/s41392-024-01757-9 · 2024 · External reference
NF-κB in inflammation and renal diseases
10.1186/s13578-015-0056-4 · 2015 · External reference
The immune system and kidney disease: basic concepts and clinical implications
10.1038/nri3523 · 2013 · External reference
Regulation and function of NF-κB transcription factors in the immune system
10.1146/annurev.immunol.021908.132641 · 2009 · External reference
NF-κB, the first quarter-century: remarkable progress and outstanding questions
10.1101/gad.183434.111 · 2012 · External reference
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
10.1038/s41392-020-00312-6 · 2020 · External reference
NF‐κB regulation: the nuclear response
10.1111/j.1582-4934.2009.00632.x · 2009 · External reference
NF-κB in renal inflammation
10.1681/asn.2010020218 · 2010 · External reference
Transcription factor-κB (NF-κB) and renal disease
10.1046/j.1523-1755.2001.059002415.x · 2001 · External reference
Innate immune pattern recognition: a cell biological perspective
10.1146/annurev-immunol-032414-112240 · 2015 · External reference
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway
10.1186/s12974-019-1538-9 · 2019 · External reference
The NLRP3 inflammasome: an overview of mechanisms of activation and regulation
10.3390/ijms20133328 · 2019 · External reference
Eupafolin nanoparticle improves acute renal injury induced by LPS through inhibiting ROS and inflammation
10.1016/j.biopha.2016.11.083 · 2017 · External reference
Inhibition of nuclear factor-κB activation attenuates tubulointerstitial nephritis induced by gentamicin
10.1159/000081558 · 2004 · External reference
Chronic inhibition of nuclear factor-κB attenuates renal injury in the 5/6 renal ablation model
10.1152/ajprenal.00184.2006 · 2007 · External reference
Small interfering RNA targeting IKKβ prevents renal ischemia-reperfusion injury in rats
10.1152/ajprenal.00547.2010 · 2011 · External reference
Synergistic inhibition of lung cancer cells by EGCG and NF-κB inhibitor BAY11-7082
10.7150/jca.34285 · 2019 · External reference
Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment
10.1016/j.biopha.2018.02.090 · 2018 · External reference
TGF-β/Smad signaling in renal fibrosis
10.3389/fphys.2015.00082 · 2015 · External reference
TGF-β/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives
10.3892/mmr.2024.13267 · 2024 · External reference
Targeting TGF-β/Smad in chronic kidney disease fibrosis: mechanisms and TCM therapeutics
2025 · External reference
Transforming growth factor-β signalling in renal fibrosis: from smads to non-coding RNAs
10.1113/jp274492 · 2018 · External reference
Role of the TGF-β/Smad signaling pathway in the transition from acute kidney injury to chronic kidney disease
10.3892/ijmm.2025.5603 · 2025 · External reference
Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis
10.1016/j.ijpharm.2024.124261 · 2024 · External reference
Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs
10.1016/j.ymthe.2023.12.009 · 2024 · External reference
Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy
10.7150/ijbs.101548 · 2025 · External reference
BMP-7 upregulates Id2 through the MAPK signaling pathway to improve diabetic tubulointerstitial fibrosis and the intervention of oxymatrine
2022 · External reference
Signaling pathways involved in diabetic renal fibrosis
2021 · External reference
Implication of the MAPK signalling pathway in the pathogenesis of diabetic nephropathy
2019 · External reference
The role of MAPK in drug-induced kidney injury
10.1155/2012/463617 · 2012 · External reference
The pathogenesis of acute kidney injury and the toxic triangle of oxygen, reactive oxygen species and nitric oxide
2011 · External reference
Oxidative stress and gene expression in sepsis
10.1093/bja/aeg034 · 2003 · External reference
Evaluation of oxidative stress and antioxidant status: correlation with the severity of sepsis
10.1111/sji.12653 · 2018 · External reference
Changes in the activity and concentration of superoxide dismutase isoenzymes (Cu/Zn SOD, MnSOD) in the blood of healthy subjects and patients with acute pancreatitis
10.3390/antiox9100948 · 2020 · External reference
Oxidative parameters differences during non-lethal and lethal sepsis development1
10.1016/j.jss.2004.11.008 · 2005 · External reference
Extracellular superoxide dismutase is necessary to maintain renal blood flow during sepsis development
10.1186/s40635-017-0130-9 · 2017 · External reference
A predictive model for progression of chronic kidney disease to kidney failure
10.1001/jama.2011.451 · 2011 · External reference
Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis
10.1001/jama.2015.18202 · 2016 · External reference
Machine learning hybrid model for the prediction of chronic kidney disease
10.1155/2023/9266889 · 2023 · External reference
A systematic review of prediction models on arteriovenous fistula: risk scores and machine learning approaches
10.1177/11297298241237830 · 2025 · External reference
A deep learning algorithm to quantify AVF stenosis and predict 6-month primary patency: a pilot study
10.1093/ckj/sfac254 · 2023 · External reference
Predicting long-term patency of radiocephalic arteriovenous fistulas with machine learning and the PREDICT-AVF web app
10.1038/s41598-025-04310-y · 2025 · External reference
Predicting 1-year successful clinical use of an arteriovenous access for hemodialysis using machine learning
10.1038/s41746-025-02187-9 · 2025 · External reference
Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches
10.1016/j.jpha.2024.100996 · 2024 · External reference
Predicting liposome formulations by the integrated machine learning and molecular modeling approaches
2023 · External reference
Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models
10.1016/j.jconrel.2024.08.015 · 2024 · External reference
Diagnosing the information limits of In vitro drug release from PLGA microparticle data
10.3390/pharmaceutics18070805 · 2026 · External reference
Two-step machine learning enables optimized nanoparticle synthesis
10.1038/s41524-021-00520-w · 2021 · External reference
Rational design of safer inorganic nanoparticles via mechanistic modeling-informed machine learning
10.1021/acsnano.5c03590 · 2025 · External reference
Evaluation of clinical prediction models (part 1): from development to external validation
10.1136/bmj-2023-074819 · 2024 · External reference
Evaluation of clinical prediction models (part 2): how to undertake an external validation study
2024 · External reference
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
10.1136/bmj-2023-078378 · 2024 · External reference
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease
10.1016/j.jconrel.2020.10.047 · 2021 · External reference
Integrating artificial intelligence and nanotechnology for precision cancer medicine
2020 · External reference
Advanced drug delivery systems for renal disorders
10.3390/gels9020115 · 2023 · External reference
Diagnosing the information limits of in vitro drug release from PLGA microparticle data
10.3390/pharmaceutics18070805 · 2026 · External reference
Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment
10.1002/adhm.201800558 · 2018 · External reference
Enhanced glomerular transfection by BMP7 gene nanocarriers inhibits CKD and promotes SOX9-dependent tubule regeneration
10.1016/j.nantod.2024.102545 · 2024 · External reference
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
10.1186/s12951-021-00900-w · 2021 · External reference
Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity
10.1016/j.jconrel.2020.01.017 · 2020 · External reference
Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats
10.1038/s41598-020-59411-7 · 2020 · External reference
Oral delivery of nanomedicine for genetic kidney disease
10.1093/pnasnexus/pgae187 · 2024 · External reference
A pH-Responsive System based on Fluorescence enhanced gold nanoparticles for renal targeting drug delivery and fibrosis therapy
10.2147/ijn.s260069 · 2020 · External reference
Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis
10.1016/j.jconrel.2022.12.059 · 2023 · External reference
Engineered extracellular vesicle-encapsulated CHIP as novel nanotherapeutics for treatment of renal fibrosis
10.1038/s41536-024-00348-0 · 2024 · External reference
Glutaminase-responsive nano-carrier for precise rejuvenation of senescent cells by restoring autophagy in chronic kidney disease treatment
10.1016/j.ijpharm.2025.125469 · 2025 · External reference
Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis
10.1016/j.biomaterials.2021.120902 · 2021 · External reference
Nanoparticle-mediated Klotho gene therapy prevents acute kidney injury to chronic kidney disease transition through regulating PPARα signaling in renal tubular epithelial cells
10.1016/j.biomaterials.2024.122926 · 2025 · External reference
A pH-Responsive system based on fluorescence enhanced gold nanoparticles for renal targeting drug delivery and fibrosis therapy
10.2147/ijn.s260069 · 2020 · External reference
Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis
10.1016/j.jconrel.2022.12.059 · 2023 · External reference
Incorporating zeolitic-imidazolate framework-8 nanoparticles into kidney scaffolds: a first step towards innovative renal therapies
10.1039/d2nr04246k · 2022 · External reference
Oral delivery of kidney targeting nanotherapeutics for polycystic kidney disease
2022 · External reference
Improved oral bioavailability and anti-chronic renal failure activity of chrysophanol via mixed polymeric micelles
10.1080/02652048.2020.1849440 · 2021 · External reference
Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease
10.2217/nnm-2017-0256 · 2017 · External reference
siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA
10.1089/nat.2014.0505 · 2015 · External reference
Controlled delivery of rosuvastatin or rapamycin through electrospun bismuth nanoparticle-infused perivascular wraps promotes arteriovenous fistula maturation
10.1021/acsami.4c06042 · 2024 · External reference
Bismuth-infused perivascular wrap facilitates delivery of mesenchymal stem cells and attenuation of neointimal hyperplasia in rat arteriovenous fistulas
10.1016/j.bioadv.2024.214052 · 2025 · External reference
1α,25-Dihydroxyvitamin D(3) encapsulated in nanoparticles prevents venous Neointimal Hyperplasia and stenosis in porcine arteriovenous fistulas
10.1681/asn.2020060832 · 2021 · External reference
Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin D3 attenuates restenosis in a murine angioplasty model
10.1038/s41598-021-84444-x · 2021 · External reference
Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model
10.1016/j.trsl.2022.06.002 · 2022 · External reference
Rosuvastatin-Eluting gold-nanoparticle-loaded perivascular wrap for enhanced arteriovenous fistula maturation in a murine model
10.1007/s42765-023-00315-2 · 2023 · External reference
Gold nanoparticles for monitoring of mesenchymal stem-cell-loaded bioresorbable polymeric wraps for arteriovenous fistula maturation
10.3390/ijms241411754 · 2023 · External reference
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
10.1016/j.drudis.2018.01.047 · 2018 · External reference
Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications
10.1016/j.nano.2014.03.017 · 2014 · External reference
Polymeric nanoparticles for drug delivery
10.1021/acs.chemrev.3c00705 · 2024 · External reference
Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles
10.3390/nano12030576 · 2022 · External reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · 2022 · External reference
Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization
10.1002/adhm.202100639 · 2022 · External reference
Micelles with ultralow critical micelle concentration as carriers for drug delivery
10.1038/s41551-018-0234-x · 2018 · External reference
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial
10.1093/ndt/gfad037 · 2023 · External reference
Quality and safety considerations for therapeutic products based on extracellular vesicles
10.1007/s11095-024-03757-4 · 2024 · External reference
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
10.1186/s13046-019-1490-7 · 2020 · External reference
Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
10.1093/ndt/gfz290 · 2020 · External reference
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
10.1093/eurheartj/ehab777 · 2022 · External reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023 · External reference
A predictive model for progression of chronic kidney disease to kidney failure
10.1001/jama.2011.451 · ExternalCitation · doi-reference
Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis
10.1001/jama.2015.18202 · ExternalCitation · doi-reference
Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment
10.1002/adhm.201800558 · ExternalCitation · doi-reference
Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization
10.1002/adhm.202100639 · ExternalCitation · doi-reference
Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery
10.1002/adma.201104763 · ExternalCitation · doi-reference
Effect of the surface modification, size, and shape on cellular uptake of nanoparticles
10.1002/cbin.10459 · ExternalCitation · doi-reference
Image‐guided tumor surgery: the emerging role of nanotechnology
10.1002/wnan.1624 · ExternalCitation · doi-reference
Influence of surface chemistry and morphology of nanoparticles on protein corona formation
10.1002/wnan.1788 · ExternalCitation · doi-reference
Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects
10.1007/s00441-011-1275-6 · ExternalCitation · doi-reference
Quality and safety considerations for therapeutic products based on extracellular vesicles
10.1007/s11095-024-03757-4 · ExternalCitation · doi-reference
Artificial intelligence in chronic kidney diseases: methodology and potential applications
10.1007/s11255-024-04165-8 · ExternalCitation · doi-reference
Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery
10.1007/s12274-018-2100-2 · ExternalCitation · doi-reference
Artificial intelligence-assisted design of nanomedicines for breast cancer diagnosis and therapy: advances, challenges, and future directions
10.1007/s12668-025-01980-w · ExternalCitation · doi-reference
Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review
10.1007/s12672-025-01821-y · ExternalCitation · doi-reference
The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations—a narrative review
10.1007/s12672-025-02469-4 · ExternalCitation · doi-reference
Rosuvastatin-Eluting gold-nanoparticle-loaded perivascular wrap for enhanced arteriovenous fistula maturation in a murine model
10.1007/s42765-023-00315-2 · ExternalCitation · doi-reference
Impact of particle elasticity on particle-based drug delivery systems
10.1016/j.addr.2016.01.007 · ExternalCitation · doi-reference
Bismuth-infused perivascular wrap facilitates delivery of mesenchymal stem cells and attenuation of neointimal hyperplasia in rat arteriovenous fistulas
10.1016/j.bioadv.2024.214052 · ExternalCitation · doi-reference
Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles
10.1016/j.biomaterials.2010.03.048 · ExternalCitation · doi-reference
Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis
10.1016/j.biomaterials.2021.120902 · ExternalCitation · doi-reference
Nanoparticle-mediated Klotho gene therapy prevents acute kidney injury to chronic kidney disease transition through regulating PPARα signaling in renal tubular epithelial cells
10.1016/j.biomaterials.2024.122926 · ExternalCitation · doi-reference
Eupafolin nanoparticle improves acute renal injury induced by LPS through inhibiting ROS and inflammation
10.1016/j.biopha.2016.11.083 · ExternalCitation · doi-reference
Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment
10.1016/j.biopha.2018.02.090 · ExternalCitation · doi-reference
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
10.1016/j.drudis.2018.01.047 · ExternalCitation · doi-reference
Prescription practices in patients with mild to moderate CKD in India
10.1016/j.ekir.2021.06.011 · ExternalCitation · doi-reference
Advances in kidney-targeted drug delivery systems
10.1016/j.ijpharm.2020.119679 · ExternalCitation · doi-reference
Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis
10.1016/j.ijpharm.2024.124261 · ExternalCitation · doi-reference
Glutaminase-responsive nano-carrier for precise rejuvenation of senescent cells by restoring autophagy in chronic kidney disease treatment
10.1016/j.ijpharm.2025.125469 · ExternalCitation · doi-reference
Size and shape effects in the biodistribution of intravascularly injected particles
10.1016/j.jconrel.2009.10.014 · ExternalCitation · doi-reference
Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity
10.1016/j.jconrel.2020.01.017 · ExternalCitation · doi-reference
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease
10.1016/j.jconrel.2020.10.047 · ExternalCitation · doi-reference
Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions
10.1016/j.jconrel.2021.04.016 · ExternalCitation · doi-reference
Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
10.1016/j.jconrel.2021.11.042 · ExternalCitation · doi-reference
Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis
10.1016/j.jconrel.2022.12.059 · ExternalCitation · doi-reference
Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients
10.1016/j.jconrel.2023.09.003 · ExternalCitation · doi-reference
Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models
10.1016/j.jconrel.2024.08.015 · ExternalCitation · doi-reference
Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches
10.1016/j.jpha.2024.100996 · ExternalCitation · doi-reference
Oxidative parameters differences during non-lethal and lethal sepsis development1
10.1016/j.jss.2004.11.008 · ExternalCitation · doi-reference
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule
10.1016/j.kint.2020.07.019 · ExternalCitation · doi-reference
KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · ExternalCitation · doi-reference
Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications
10.1016/j.nano.2014.03.017 · ExternalCitation · doi-reference
Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases
10.1016/j.nano.2015.04.015 · ExternalCitation · doi-reference
Enhanced glomerular transfection by BMP7 gene nanocarriers inhibits CKD and promotes SOX9-dependent tubule regeneration
10.1016/j.nantod.2024.102545 · ExternalCitation · doi-reference
Where are they now: spatial and molecular diversity of tissue-resident macrophages in the kidney
10.1016/j.semnephrol.2022.10.002 · ExternalCitation · doi-reference
Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity
10.1016/j.tox.2010.08.013 · ExternalCitation · doi-reference
Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
10.1016/j.toxrep.2020.12.022 · ExternalCitation · doi-reference
Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model
10.1016/j.trsl.2022.06.002 · ExternalCitation · doi-reference
RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis
10.1016/j.trsl.2024.03.003 · ExternalCitation · doi-reference
Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs
10.1016/j.ymthe.2023.12.009 · ExternalCitation · doi-reference
Chronic kidney disease
10.1016/s0140-6736(21)00519-5 · ExternalCitation · doi-reference
Polymeric nanoparticles for drug delivery
10.1021/acs.chemrev.3c00705 · ExternalCitation · doi-reference
Controlled delivery of rosuvastatin or rapamycin through electrospun bismuth nanoparticle-infused perivascular wraps promotes arteriovenous fistula maturation
10.1021/acsami.4c06042 · ExternalCitation · doi-reference
Rational design of safer inorganic nanoparticles via mechanistic modeling-informed machine learning
10.1021/acsnano.5c03590 · ExternalCitation · doi-reference
Quantitative assessment of nanoparticle biodistribution by Fluorescence Imaging, revisited
10.1021/acsnano.8b02881 · ExternalCitation · doi-reference
Impact of nanotechnology on drug delivery
10.1021/nn900002m · ExternalCitation · doi-reference
Renal clearance of quantum dots
10.1038/nbt1340 · ExternalCitation · doi-reference
Mechanism of hard-nanomaterial clearance by the liver
10.1038/nmat4718 · ExternalCitation · doi-reference
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface
10.1038/nnano.2012.237 · ExternalCitation · doi-reference
The immune system and kidney disease: basic concepts and clinical implications
10.1038/nri3523 · ExternalCitation · doi-reference
Nanomedicines for renal disease: current status and future applications
10.1038/nrneph.2016.156 · ExternalCitation · doi-reference
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
10.1038/s41392-020-00312-6 · ExternalCitation · doi-reference
NF-κB in biology and targeted therapy: new insights and translational implications
10.1038/s41392-024-01757-9 · ExternalCitation · doi-reference
High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches
10.1038/s41467-025-56223-z · ExternalCitation · doi-reference
Two-step machine learning enables optimized nanoparticle synthesis
10.1038/s41524-021-00520-w · ExternalCitation · doi-reference
Engineered extracellular vesicle-encapsulated CHIP as novel nanotherapeutics for treatment of renal fibrosis
10.1038/s41536-024-00348-0 · ExternalCitation · doi-reference
Micelles with ultralow critical micelle concentration as carriers for drug delivery
10.1038/s41551-018-0234-x · ExternalCitation · doi-reference
Minimum information reporting in bio–nano experimental literature
10.1038/s41565-018-0246-4 · ExternalCitation · doi-reference
Physiological principles underlying the kidney targeting of renal nanomedicines
10.1038/s41581-024-00819-z · ExternalCitation · doi-reference
Chronic kidney disease and the global public health agenda: an international consensus
10.1038/s41581-024-00820-6 · ExternalCitation · doi-reference
Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats
10.1038/s41598-020-59411-7 · ExternalCitation · doi-reference
Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin D3 attenuates restenosis in a murine angioplasty model
10.1038/s41598-021-84444-x · ExternalCitation · doi-reference
Predicting long-term patency of radiocephalic arteriovenous fistulas with machine learning and the PREDICT-AVF web app
10.1038/s41598-025-04310-y · ExternalCitation · doi-reference
Predicting 1-year successful clinical use of an arteriovenous access for hemodialysis using machine learning
10.1038/s41746-025-02187-9 · ExternalCitation · doi-reference
Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice
10.1038/s42003-021-02546-8 · ExternalCitation · doi-reference
Incorporating zeolitic-imidazolate framework-8 nanoparticles into kidney scaffolds: a first step towards innovative renal therapies
10.1039/d2nr04246k · ExternalCitation · doi-reference
Transcription factor-κB (NF-κB) and renal disease
10.1046/j.1523-1755.2001.059002415.x · ExternalCitation · doi-reference
GFR estimation: from physiology to public health
10.1053/j.ajkd.2013.12.006 · ExternalCitation · doi-reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · ExternalCitation · doi-reference
A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis
10.1073/pnas.2305662120 · ExternalCitation · doi-reference
Improved oral bioavailability and anti-chronic renal failure activity of chrysophanol via mixed polymeric micelles
10.1080/02652048.2020.1849440 · ExternalCitation · doi-reference
siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA
10.1089/nat.2014.0505 · ExternalCitation · doi-reference
Oxidative stress and gene expression in sepsis
10.1093/bja/aeg034 · ExternalCitation · doi-reference
A deep learning algorithm to quantify AVF stenosis and predict 6-month primary patency: a pilot study
10.1093/ckj/sfac254 · ExternalCitation · doi-reference
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
10.1093/eurheartj/ehab777 · ExternalCitation · doi-reference
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial
10.1093/ndt/gfad037 · ExternalCitation · doi-reference
Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
10.1093/ndt/gfz290 · ExternalCitation · doi-reference
Oral delivery of nanomedicine for genetic kidney disease
10.1093/pnasnexus/pgae187 · ExternalCitation · doi-reference
NF-κB, the first quarter-century: remarkable progress and outstanding questions
10.1101/gad.183434.111 · ExternalCitation · doi-reference
Effects of cerium oxide nanoparticles on adenine‐induced chronic kidney disease model rats
10.1111/ggi.14739 · ExternalCitation · doi-reference
NF‐κB regulation: the nuclear response
10.1111/j.1582-4934.2009.00632.x · ExternalCitation · doi-reference
Evaluation of oxidative stress and antioxidant status: correlation with the severity of sepsis
10.1111/sji.12653 · ExternalCitation · doi-reference
Transforming growth factor-β signalling in renal fibrosis: from smads to non-coding RNAs
10.1113/jp274492 · ExternalCitation · doi-reference
Evaluation of clinical prediction models (part 1): from development to external validation
10.1136/bmj-2023-074819 · ExternalCitation · doi-reference
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
10.1136/bmj-2023-078378 · ExternalCitation · doi-reference
Innate immune pattern recognition: a cell biological perspective
10.1146/annurev-immunol-032414-112240 · ExternalCitation · doi-reference
Regulation and function of NF-κB transcription factors in the immune system
10.1146/annurev.immunol.021908.132641 · ExternalCitation · doi-reference
Chronic inhibition of nuclear factor-κB attenuates renal injury in the 5/6 renal ablation model
10.1152/ajprenal.00184.2006 · ExternalCitation · doi-reference
Small interfering RNA targeting IKKβ prevents renal ischemia-reperfusion injury in rats
10.1152/ajprenal.00547.2010 · ExternalCitation · doi-reference
The role of MAPK in drug-induced kidney injury
10.1155/2012/463617 · ExternalCitation · doi-reference
Machine learning hybrid model for the prediction of chronic kidney disease
10.1155/2023/9266889 · ExternalCitation · doi-reference
Inhibition of nuclear factor-κB activation attenuates tubulointerstitial nephritis induced by gentamicin
10.1159/000081558 · ExternalCitation · doi-reference
A systematic review of prediction models on arteriovenous fistula: risk scores and machine learning approaches
10.1177/11297298241237830 · ExternalCitation · doi-reference
Promoting plant-based therapies for chronic kidney disease
10.1177/2515690x221079688 · ExternalCitation · doi-reference
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
10.1186/1477-3155-9-55 · ExternalCitation · doi-reference
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
10.1186/s12951-021-00900-w · ExternalCitation · doi-reference
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway
10.1186/s12974-019-1538-9 · ExternalCitation · doi-reference
Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions
10.1186/s12989-017-0206-4 · ExternalCitation · doi-reference
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
10.1186/s13046-019-1490-7 · ExternalCitation · doi-reference
NF-κB in inflammation and renal diseases
10.1186/s13578-015-0056-4 · ExternalCitation · doi-reference
Extracellular superoxide dismutase is necessary to maintain renal blood flow during sepsis development
10.1186/s40635-017-0130-9 · ExternalCitation · doi-reference
NF-κB in renal inflammation
10.1681/asn.2010020218 · ExternalCitation · doi-reference
1α,25-Dihydroxyvitamin D(3) encapsulated in nanoparticles prevents venous Neointimal Hyperplasia and stenosis in porcine arteriovenous fistulas
10.1681/asn.2020060832 · ExternalCitation · doi-reference
A pH-Responsive system based on fluorescence enhanced gold nanoparticles for renal targeting drug delivery and fibrosis therapy
10.2147/ijn.s260069 · ExternalCitation · doi-reference
Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys
10.2147/ijn.s443168 · ExternalCitation · doi-reference
Research and application prospect of nanomedicine in kidney disease: a bibliometric analysis from 2003 to 2024
10.2147/ijn.s510016 · ExternalCitation · doi-reference
Nanotechnology for the environment and medicine
10.2174/1389557515666150709105129 · ExternalCitation · doi-reference
Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?
10.2215/cjn.03740907 · ExternalCitation · doi-reference
Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease
10.2217/nnm-2017-0256 · ExternalCitation · doi-reference
From bits to atoms: machine learning and nanotechnology for cancer therapy
10.26502/jnr.2688-85210042 · ExternalCitation · doi-reference
Recent advances in understanding the protein Corona of nanoparticles and in the formulation of “Stealthy” nanomaterials
10.3389/fbioe.2020.00166 · ExternalCitation · doi-reference
TGF-β1 signaling: immune dynamics of chronic kidney diseases
10.3389/fmed.2021.628519 · ExternalCitation · doi-reference
The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis
10.3389/fphar.2023.1335094 · ExternalCitation · doi-reference
TGF-β/Smad signaling in renal fibrosis
10.3389/fphys.2015.00082 · ExternalCitation · doi-reference
Changes in the activity and concentration of superoxide dismutase isoenzymes (Cu/Zn SOD, MnSOD) in the blood of healthy subjects and patients with acute pancreatitis
10.3390/antiox9100948 · ExternalCitation · doi-reference
Advanced drug delivery systems for renal disorders
10.3390/gels9020115 · ExternalCitation · doi-reference
The NLRP3 inflammasome: an overview of mechanisms of activation and regulation
10.3390/ijms20133328 · ExternalCitation · doi-reference
Gold nanoparticles for monitoring of mesenchymal stem-cell-loaded bioresorbable polymeric wraps for arteriovenous fistula maturation
10.3390/ijms241411754 · ExternalCitation · doi-reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · ExternalCitation · doi-reference
Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles
10.3390/nano12030576 · ExternalCitation · doi-reference
Diagnosing the information limits of in vitro drug release from PLGA microparticle data
10.3390/pharmaceutics18070805 · ExternalCitation · doi-reference
Role of the TGF-β/Smad signaling pathway in the transition from acute kidney injury to chronic kidney disease
10.3892/ijmm.2025.5603 · ExternalCitation · doi-reference
TGF-β/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives
10.3892/mmr.2024.13267 · ExternalCitation · doi-reference
Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology
10.3934/bioeng.2024026 · ExternalCitation · doi-reference
National trends and projection of chronic kidney disease incidence according to etiology from 1990 to 2030 in Iran: a Bayesian age-period-cohort modeling study
10.4178/epih.e2023027 · ExternalCitation · doi-reference
Nephrotoxicity induced by different diameters of sphere gold nanoparticles with special emphasis on the nephroprotective role of quercetin
10.5455/ovj.2023.v13.i6.7 · ExternalCitation · doi-reference
Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy
10.7150/ijbs.101548 · ExternalCitation · doi-reference
Synergistic inhibition of lung cancer cells by EGCG and NF-κB inhibitor BAY11-7082
10.7150/jca.34285 · ExternalCitation · doi-reference
